Celladon Shares May Have Upside to $70
The developer of gene therapy for heart failure to announce pivotal trial results.
We are initiating coverage of Celladon with a Buy rating and target of $70.
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance ofCUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising for future success
CyberArk's new customers include 40% of Fortune 100 companies as well as many of the world's majorbanks.CyberArk is one of the highest ranked stocks by Composite Rating in the highly ranked security software industry group.
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
Adam Feuerstein Follow
Significant data is an indication that CAR-T therapies have a role as a treatment in the much larger solitumor cancer market. To date, all of the excitement surrounding CAR-T has come from very high remission rates in patients with advanced blood cancers.
Bought - Great Entry
Bloomberg Report - ADRO The Biotech To Watch
By: Paul Barrett
ADURO BIOTECH ( ADRO ) Aduro is a clinical-stage cancer immuno-oncology company and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration just as Bluebird (BLUE ) received.
there's a reason
do the DD